Date published: 2025-12-24

1-800-457-3801

SCBT Portrait Logo
Seach Input

AWAT1 Inhibitors

AWAT1 inhibitors encompass a variety of compounds that interfere with the enzyme's ability to synthesize wax esters by targeting different aspects of fatty acid metabolism. One class of inhibitors operates by causing substrate inhibition, where excess amounts of long-chain fatty acyl-CoAs accumulate to levels that impede AWAT1's enzymatic activity. This form of inhibition is characterized by a decrease in enzyme efficiency as substrate concentrations rise beyond optimal levels. Another mechanism involves competitive inhibition, exemplified by compounds that compete with AWAT1 substrates for binding, which can inhibit the enzyme by occupying its active site. Additionally, some inhibitors target upstream processes in fatty acid metabolism: they inhibit fatty acid synthase or acyl-CoA synthetase, leading to reduced availability of fatty acyl-CoA substrates necessary for AWAT1 function. In this way, the inhibitors indirectly reduce AWAT1 activity by limiting the pool of substrates required for wax ester synthesis.

Further diminishing AWAT1's activity, other inhibitors act by disrupting the transport and utilization of fatty acyl-CoAs, which are critical substrates for the enzyme's function. For instance, compounds that inhibit carnitine palmitoyltransferase-1 block the transfer of fatty acyl-CoAs into mitochondria for β-oxidation, resulting in increased cytosolic levels of these molecules. This increase can lead to substrate inhibition of AWAT1, as the enzyme becomes overwhelmed by the excessive substrate presence. Moreover, lipase inhibitors contribute to the indirect inhibition of AWAT1 by preventing the conversion of free fatty acids into triglycerides, leading to an accumulation of free fatty acids. This accumulation can suppress the synthesis of fatty acyl-CoA, indirectly reducing AWAT1 activity. Additionally, inhibitors of acetyl-CoA carboxylase play a role in this intricate network by limiting the production of malonyl-CoA, thereby alleviating the competitive inhibition of AWAT1 and contributing to its overall inhibition.

SEE ALSO...

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Oleoyl coenzyme A

1716-06-9sc-286621
sc-286621A
5 mg
25 mg
$230.00
$939.00
(0)

Can cause substrate inhibition of AWAT1 by overwhelming the enzyme with high substrate concentrations, leading to a decrease in its activity.

Lithium

7439-93-2sc-252954
50 g
$214.00
(0)

Competes with the acyl-CoA substrates of AWAT1 for binding sites, which can inhibit the enzyme’s activity through competitive inhibition.

Cerulenin (synthetic)

17397-89-6sc-200827
sc-200827A
sc-200827B
5 mg
10 mg
50 mg
$158.00
$306.00
$1186.00
9
(1)

Cerulenin is a fatty acid synthesis inhibitor that binds to the active site of fatty acid synthase, leading to reduced availability of fatty acyl-CoAs, which are substrates for AWAT1, thus indirectly inhibiting AWAT1 activity.

C75 (racemic)

191282-48-1sc-202511
sc-202511A
sc-202511B
1 mg
5 mg
10 mg
$71.00
$202.00
$284.00
9
(1)

C75 is a synthetic fatty acid synthase inhibitor. By inhibiting fatty acid synthase, C75 reduces the levels of fatty acyl-CoA substrates necessary for AWAT1 activity, leading to its functional inhibition.

Triacsin C Solution in DMSO

76896-80-5sc-200574
sc-200574A
100 µg
1 mg
$149.00
$826.00
14
(1)

This compound inhibits long-chain acyl-CoA synthetase, which is responsible for converting free fatty acids into fatty acyl-CoA. Inhibition of this enzyme decreases the availability of substrates for AWAT1, thereby inhibiting its activity.

TOFA (5-(Tetradecyloxy)-2-furoic acid)

54857-86-2sc-200653
sc-200653A
10 mg
50 mg
$95.00
$367.00
15
(1)

TOFA is an inhibitor of acetyl-CoA carboxylase, which reduces malonyl-CoA levels, thereby reducing the competition for acyl-CoA substrates and indirectly inhibiting AWAT1.

rac Perhexiline Maleate

6724-53-4sc-460183
10 mg
$184.00
(0)

Perhexiline inhibits carnitine palmitoyltransferase-1, which reduces the transport of fatty acyl-CoAs into mitochondria for β-oxidation. This leads to increased cytosolic fatty acyl-CoA levels that can inhibit AWAT1 through substrate inhibition.

Lipase Inhibitor, THL

96829-58-2sc-203108
50 mg
$51.00
7
(1)

A lipase inhibitor that can increase the levels of free fatty acids in the cell by preventing their conversion into triglycerides. The resultant increase in free fatty acids can inhibit the synthesis of fatty acyl-CoA, thus indirectly inhibiting AWAT1.

(+)-Etomoxir sodium salt

828934-41-4sc-215009
sc-215009A
5 mg
25 mg
$148.00
$496.00
3
(2)

Inhibits carnitine palmitoyltransferase-1, limiting the utilization of fatty acyl-CoAs for β-oxidation and leading to increased cytosolic levels that can inhibit AWAT1 through substrate inhibition.